Wilmington PharmaTech invests $18m in new research, manufacturing facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Milkos)
(Image: Getty/Milkos)

Related tags: CDMO, PharmaTech, Research, Manufacturing

The DE-based CDMO plans to hire up to 139 new employees as part of an $18m investment into a new research and manufacturing facility.

The contract development and manufacturing organization (CDMO) currently employs 37 staff in the US across several locations in Newark, DE, where the new large-scale pharmaceutical production facility will be located. It also has operations in Suzhou Jiangsu, China.

"This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US,"​ said Hui-Yin Harry Li, PhD, president and CEO of Wilmington PharmaTech in a press release.

"This expansion scales up operations and significantly enhances offerings to our clients in API manufacturing and related services. It also expands our portfolio of research, development, and potential commercial API services.”

Dr. Ke Li, PMP, PharmaTech's director of operations, yesterday presented the company's plans to the Council on Development Finance, requesting a $300,400 performance-based grant to support adding new jobs and a grant of $360,000 for assistance with capital costs.

PharmaTech has not responded to a request for comment.


Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more